成分檢驗報告
比菲德氏菌 BB536
英文名稱:Bifidobacterium longum BB536
- 共有幾筆評級
- 5 筆
- 資料日期
- 2026-06-09
- 台灣規定
- 台灣有獨立規範
檢驗結果
| 用在哪裡 | 證據等級 | 分數(滿分 100) | 要注意的地方 |
|---|---|---|---|
| 過敏性鼻炎 | B 初步證據 | 64 |
|
| 潰瘍性結腸炎 | B 初步證據 | 59 |
|
| 老年免疫 | C 薄弱證據 | 55 |
|
| 嬰兒腸絞痛 | U 未驗證 | 43 |
|
| 困難梭狀芽孢桿菌感染 | U 未驗證 | 40 |
|
逐筆明細
保健成分 × 適應症
比菲德氏菌 BB536 × 過敏性鼻炎
白話說:有初步證據,但研究規模還小,別當成定論。
發布狀態:可參考,但附帶但書
- 第三方營養資料庫(國際)
展開原文引用
「Probiotics (Also known as: probiotic) are microorganisms that can have a positive effect on health. Examine catalogs evidence at the umbrella 'Probiotics' level rather than for individual strains such」 - 美國 FDA 態度:支持
展開原文引用
「GRN No. 877 — Bifidobacterium longum BB536. Intended use: ingredient in term infant formula at a level of 1 x 10^8 CFU per gram of product. FDA closure date: December 26, 2019. FDA letter: 'FDA has no questions' regarding the safety of Bifidobacterium longum BB536 when used as described in the notice. (Earlier GRN 268 covered use in conventional foods/beverages.)」 - 歐盟 EFSA 態度:持保留
展開原文引用
「Scientific Opinion on the substantiation of health claims related to Bifidobacterium longum BB536 and improvement of bowel regularity (ID 3004), normal resistance to cedar pollen allergens (ID 3006), and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 3005) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Conclusion: Bifidobacterium longum BB536 does not improve…」
評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v7。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 證據資料庫原始頁面
保健成分 × 適應症
比菲德氏菌 BB536 × 潰瘍性結腸炎
白話說:有初步證據,但研究規模還小,別當成定論。
發布狀態:可參考,但附帶但書
- 第三方營養資料庫(國際)
展開原文引用
「Probiotics (Also known as: probiotic) are microorganisms that can have a positive effect on health. Examine catalogs evidence at the umbrella 'Probiotics' level rather than for individual strains such」 - 美國 FDA 態度:支持
展開原文引用
「GRN No. 877 — Bifidobacterium longum BB536. Intended use: ingredient in term infant formula at a level of 1 x 10^8 CFU per gram of product. FDA closure date: December 26, 2019. FDA letter: 'FDA has no questions' regarding the safety of Bifidobacterium longum BB536 when used as described in the notice. (Earlier GRN 268 covered use in conventional foods/beverages.)」 - 歐盟 EFSA 態度:持保留
展開原文引用
「Scientific Opinion on the substantiation of health claims related to Bifidobacterium longum BB536 and improvement of bowel regularity (ID 3004), normal resistance to cedar pollen allergens (ID 3006), and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 3005) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Conclusion: Bifidobacterium longum BB536 does not improve…」
評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v7。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 證據資料庫原始頁面
保健成分 × 適應症
比菲德氏菌 BB536 × 老年免疫
白話說:證據還很薄弱,不足以當成有效的療法。
發布狀態:可參考,但附帶但書
- 第三方營養資料庫(國際)
展開原文引用
「Probiotics (Also known as: probiotic) are microorganisms that can have a positive effect on health. Examine catalogs evidence at the umbrella 'Probiotics' level rather than for individual strains such」 - 美國 FDA 態度:支持
展開原文引用
「GRN No. 877 — Bifidobacterium longum BB536. Intended use: ingredient in term infant formula at a level of 1 x 10^8 CFU per gram of product. FDA closure date: December 26, 2019. FDA letter: 'FDA has no questions' regarding the safety of Bifidobacterium longum BB536 when used as described in the notice. (Earlier GRN 268 covered use in conventional foods/beverages.)」 - 歐盟 EFSA 態度:持保留
展開原文引用
「Scientific Opinion on the substantiation of health claims related to Bifidobacterium longum BB536 and improvement of bowel regularity (ID 3004), normal resistance to cedar pollen allergens (ID 3006), and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 3005) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Conclusion: Bifidobacterium longum BB536 does not improve…」
評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v7。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 證據資料庫原始頁面
保健成分 × 適應症
比菲德氏菌 BB536 × 嬰兒腸絞痛
白話說:目前沒有可靠的人體研究,無法下定論。
發布狀態:證據尚不足以下判斷
- 第三方營養資料庫(國際)
展開原文引用
「Probiotics (Also known as: probiotic) are microorganisms that can have a positive effect on health. Examine catalogs evidence at the umbrella 'Probiotics' level rather than for individual strains such」 - 美國 FDA 態度:支持
展開原文引用
「GRN No. 877 — Bifidobacterium longum BB536. Intended use: ingredient in term infant formula at a level of 1 x 10^8 CFU per gram of product. FDA closure date: December 26, 2019. FDA letter: 'FDA has no questions' regarding the safety of Bifidobacterium longum BB536 when used as described in the notice. (Earlier GRN 268 covered use in conventional foods/beverages.)」 - 歐盟 EFSA 態度:持保留
展開原文引用
「Scientific Opinion on the substantiation of health claims related to Bifidobacterium longum BB536 and improvement of bowel regularity (ID 3004), normal resistance to cedar pollen allergens (ID 3006), and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 3005) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Conclusion: Bifidobacterium longum BB536 does not improve…」
評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v8。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 證據資料庫原始頁面
保健成分 × 適應症
比菲德氏菌 BB536 × 困難梭狀芽孢桿菌感染
白話說:目前沒有可靠的人體研究,無法下定論。
發布狀態:證據尚不足以下判斷
- 第三方營養資料庫(國際)
展開原文引用
「Probiotics (Also known as: probiotic) are microorganisms that can have a positive effect on health. Examine catalogs evidence at the umbrella 'Probiotics' level rather than for individual strains such」 - 美國 FDA 態度:支持
展開原文引用
「GRN No. 877 — Bifidobacterium longum BB536. Intended use: ingredient in term infant formula at a level of 1 x 10^8 CFU per gram of product. FDA closure date: December 26, 2019. FDA letter: 'FDA has no questions' regarding the safety of Bifidobacterium longum BB536 when used as described in the notice. (Earlier GRN 268 covered use in conventional foods/beverages.)」 - 歐盟 EFSA 態度:持保留
展開原文引用
「Scientific Opinion on the substantiation of health claims related to Bifidobacterium longum BB536 and improvement of bowel regularity (ID 3004), normal resistance to cedar pollen allergens (ID 3006), and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 3005) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Conclusion: Bifidobacterium longum BB536 does not improve…」
評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v8。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 證據資料庫原始頁面